Biblio
Export 5957 results:
Author Title Type Year Filters: First Letter Of Last Name is H [Clear All Filters]
“What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”, J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
, “What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”, J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
, “The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 803-814, 2018.
, “The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 803-814, 2018.
, “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
, “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
, “Different Expression Patterns of Amyloid-β Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid-β Pathogenesis.”, J Alzheimers Dis, vol. 51, no. 1, pp. 179-95, 2016.
, “microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 113-123, 2018.
, “The Evolution of Caregiver Burden in Frontotemporal Dementia with and without Amyotrophic Lateral Sclerosis.”, J Alzheimers Dis, vol. 49, no. 3, pp. 875-85, 2016.
, “The Evolution of Caregiver Burden in Frontotemporal Dementia with and without Amyotrophic Lateral Sclerosis.”, J Alzheimers Dis, vol. 49, no. 3, pp. 875-85, 2016.
, “Examining the Relationship Between Autobiographical Memory Impairment and Carer Burden in Dementia Syndromes.”, J Alzheimers Dis, vol. 51, no. 1, pp. 237-48, 2016.
, “A Comparison of Well-Being of Carers of People with Dementia and Their Ability to Manage Before and During the COVID-19 Pandemic: Findings from the IDEAL Study.”, J Alzheimers Dis, vol. 88, no. 2, pp. 679-692, 2022.
, “Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.”, J Alzheimers Dis, vol. 49, no. 4, pp. 991-1003, 2016.
, “Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.”, J Alzheimers Dis, vol. 49, no. 4, pp. 991-1003, 2016.
, “Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1209-24, 2016.
, “Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1209-24, 2016.
, “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
, “Intranasal TAT-haFGF Improves Cognition and Amyloid-β Pathology in an AβPP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 985-90, 2016.
, “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.
, “Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults.”, J Alzheimers Dis, vol. 28, no. 1, pp. 93-107, 2012.
, “Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.”, Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
, “Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 3, pp. 765-78, 2016.
, “Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.”, J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
,